The Board of Directors of
In accordance with the resolutions by the 2020 and 2021 annual general meeting, the Board of Directors of BONESUPPORT has resolved to execute transfer of 549,132 so called performance shares (ordinary shares) to the participants in the incentive programs LTI 2020 and LTI 2021, in accordance with the terms of the programs. The transfer is made without consideration.
In order to secure social security contributions in respect of LTI 2021 and Board-LTI 2021, the 2023 annual general meeting authorized BONESUPPORT’s Board of Directors to, on one or several occasions before the 2024 annual general meeting, resolve on transfer of own ordinary shares on Nasdaq Stockholm. Based on the authorization of the general meeting, the Board of Directors has resolved to instruct
In order to execute the above transfers, the Board of Directors has also resolved on conversion of 663,745 own series C shares into the corresponding number of ordinary shares.
In order ensure that BONESUPPORT can fulfill its obligations under the incentive program LTI 2023 resolved by the 2023 annual general meeting, the 2023 annual general meeting also authorized the Board of Directors to resolve on a directed issue of redeemable and convertible series C shares and repurchase of all issued series C shares through a directed acquisition offer to all holders of series C shares. Based on the authorization of the general meeting, the Board of Directors has resolved on a directed issue of 486,840 series C shares to
Prior to the delivery of performance shares to employees within the
The total number of shares in BONESUPPORT at the time of this press release amounts to 66,197,635, of which 65,055,575 ordinary shares and 1,142,060 series C shares. BONESUPPORT holds at the time of this press release no own ordinary shares and 1,142,060 own series C shares, intended for ongoing incentive programs. After the ongoing conversion of series C shares into ordinary shares and the ongoing issue of series C shares, the total number of shares will amount to 66,684,475, of which 65,719,320 ordinary shares and 965,155 series C shares, and after the transfer of ordinary shares and the repurchase of series C shares as set out above, BONESUPPORT will hold no own ordinary shares and 965,155 own series C shares, intended for ongoing incentive programs.
The series C shares carry one-tenth of a vote per share and do not entitle to dividends.
© Modular Finance, source